World's Best Scientists 2026 revealed!
Martin Bornhäuser

Martin Bornhäuser

D-Index & Metrics

Medicine

D-Index
109
Citations
46267
World Ranking
5753
National Ranking
323

Martin Bornhäuser publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Martin Bornhäuser sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 918 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Martin Bornhäuser D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Martin Bornhäuser sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Martin Bornhäuser is affiliated with TU Dresden in Germany and has a significant body of research primarily focused on medical sciences. Their work spans several subfields including hematology, molecular biology, genetics, oncology, and public health, environmental and occupational health. The primary domain of expertise is medicine, with a particular emphasis on hematological malignancies.

Their research covers multiple topics, notably:

  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Chronic Myeloid Leukemia Treatments
  • Cancer Genomics and Diagnostics

Bornhäuser has contributed extensively to publications in various scientific venues, with frequent appearances in:

  • Blood (66 publications)
  • Bone Marrow Transplantation (20 publications)
  • Leukemia (17 publications)
  • HemaSphere (16 publications)
  • Blood Advances (13 publications)

Frequent co-authors who have collaborated with Bornhäuser include:

  • Christoph Röllig (126 collaborations)
  • Uwe Platzbecker (113 collaborations)
  • Hubert Serve (92 collaborations)
  • Johannes Schetelig (88 collaborations)
  • Jan Moritz Middeke (85 collaborations)

Among recent scientific papers associated with the field and relevant to their research interests are:

  • Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN), 2020, Journal of Clinical Oncology
  • Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia, 2020, Science Translational Medicine
  • Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update, 2021, Frontiers in Cell and Developmental Biology
  • CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome, 2021, Blood
  • Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML, 2021, Blood

Best Publications

  • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

    Christian Thiede;Christine Steudel;Brigitte Mohr;Markus Schaich

  • Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

    Joachim Oswald;Sabine Boxberger;Birgitte Jørgensen;Silvia Feldmann

  • Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger

  • Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

    Christoph Schmid;Myriam Labopin;Arnon Nagler;Martin Bornhäuser

  • Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

    Andreas Burchert;Gesine Bug;Lea V. Fritz;Jürgen Finke

  • Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

    Nicolaus Kröger;Ernst Holler;Guido Kobbe;Martin Bornhäuser

  • Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

    Sally Arai;Mukta Arora;Tao Wang;Tao Wang;Stephen R. Spellman

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney

  • Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

    Barbara Wassmann;Heike Pfeifer;Nicola Goekbuget;Dietrich W. Beelen

  • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

    Platzbecker U;Wermke M;Radke J;Oelschlaegel U

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation

    Roy F. Chemaly;Andrew J. Ullmann;Susanne Stoelben;Marie Paule Richard

  • Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

    Gérard Socié;Claudia Schmoor;Wolfgang A. Bethge;Hellmut D. Ottinger

  • Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

    M von Bonin;F Stölzel;A Goedecke;K Richter

  • Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

    J. Schetelig;C. Thiede;M. Bornhäuser;R. Schwerdtfeger

  • Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

    A Ehninger;M Kramer;C Röllig;C Thiede

  • Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.

    C Thiede;M Florek;M Bornhäuser;M Ritter

  • Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

    Uwe Platzbecker;Jan Moritz Middeke;Katja Sockel;Regina Herbst

  • Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

    Martin Bornhäuser;Joachim Kienast;Rudolf Trenschel;Andreas Burchert

  • Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

    Christoph Röllig;Martin Bornhäuser;Christian Thiede;Franziska Taube

Frequent Co-Authors

Marc Schmitz
Marc Schmitz TU Dresden
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Michael Bachmann
Michael Bachmann Helmholtz-Zentrum Dresden-Rossendorf
Hubert Serve
Hubert Serve Goethe University Frankfurt
Jürgen Finke
Jürgen Finke University of Freiburg
Carsten Werner
Carsten Werner Leibniz-Institut für Polymerforschung Dresden e. V.
Hermann Einsele
Hermann Einsele University of Würzburg
Wolfgang E. Berdel
Wolfgang E. Berdel University of Münster

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative medical education pathways can offer greater flexibility for students with varying backgrounds or schedules. Many registered nurses looking to advance their careers consider the rn to bsn online without clinicals option. This pathway is ideal for employed RNs who wish to earn a bachelor’s degree without having to complete additional hands-on clinical hours.

For those seeking advanced practice roles, the demand for accelerated dnp programs online has increased. These programs allow students to complete doctoral-level studies rapidly, helping them enter leadership or specialist positions faster. In addition, some students prefer dnp programs without dissertation, which eliminate the intensive research component, focusing instead on practical leadership skills required in the healthcare setting.

If you’re just starting on your nursing journey, the fastest lpn program options are worth considering. These fast-track options provide a quick pathway into the workforce, making them attractive for those eager to begin careers in patient care. Online degrees and diverse program designs are shaping new, flexible paths toward advancement in medicine and healthcare.

Best Scientists Citing Martin Bornhäuser

Trending Scientists

Recently Published Articles